According to the Smart Finance app, Regent Pacific (00575) has released its six-month performance ending on June 30, 2024, with earnings of 0.123 million USD, a decrease of 28.9% compared to the same period last year; a net loss of 2.621 million USD, a decrease of 78.5% compared to the same period last year; and a basic loss per share of 1.148 cents USD.

The company's business focus has undergone restructuring and simplification, which has filled the company with confidence in the future prospects of the group and shareholders. The company will: continue to seek successful commercialization of FortacinTM/SenstendTM in the remaining major markets including the USA, China, Southeast Asia, Japan, Latin America, and the Middle East; commercialize its deep learning aging clock technology and MindAge products, as well as collaborate with clinics, laboratories, and insurance companies through the provision of AgeMetricTM reports and online Software as a Service (SaaS) platforms; and continue to implement the existing strategy of seeking strategy and value-driven investments in the field of medical care and life sciences.